ATE185341T1 - 4,9-ethano-benzo(f)isoindolderivate als farnesyl transferase inhibitoren - Google Patents

4,9-ethano-benzo(f)isoindolderivate als farnesyl transferase inhibitoren

Info

Publication number
ATE185341T1
ATE185341T1 AT96924952T AT96924952T ATE185341T1 AT E185341 T1 ATE185341 T1 AT E185341T1 AT 96924952 T AT96924952 T AT 96924952T AT 96924952 T AT96924952 T AT 96924952T AT E185341 T1 ATE185341 T1 AT E185341T1
Authority
AT
Austria
Prior art keywords
ethano
benzo
transferase inhibitors
farnesyl transferase
isoindole derivatives
Prior art date
Application number
AT96924952T
Other languages
English (en)
Inventor
Alain Commercon
Alain Lebrun
Patrick Mailliet
Jean-Francois Peyronel
Fabienne Sounigo
Alain Truchon
Martine Zucco
Original Assignee
Rhone Poulenc Rorer Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone Poulenc Rorer Sa filed Critical Rhone Poulenc Rorer Sa
Application granted granted Critical
Publication of ATE185341T1 publication Critical patent/ATE185341T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/72—4,7-Endo-alkylene-iso-indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT96924952T 1995-07-10 1996-07-08 4,9-ethano-benzo(f)isoindolderivate als farnesyl transferase inhibitoren ATE185341T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9508296A FR2736641B1 (fr) 1995-07-10 1995-07-10 Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
ATE185341T1 true ATE185341T1 (de) 1999-10-15

Family

ID=9480830

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96924952T ATE185341T1 (de) 1995-07-10 1996-07-08 4,9-ethano-benzo(f)isoindolderivate als farnesyl transferase inhibitoren

Country Status (32)

Country Link
US (1) US5936097A (de)
EP (1) EP0839133B1 (de)
JP (1) JPH11511123A (de)
KR (1) KR19990028856A (de)
CN (1) CN1096448C (de)
AR (1) AR003143A1 (de)
AT (1) ATE185341T1 (de)
AU (1) AU712194B2 (de)
BR (1) BR9609440A (de)
CA (1) CA2224414A1 (de)
CO (1) CO4700457A1 (de)
CZ (1) CZ291620B6 (de)
DE (1) DE69604588T2 (de)
DK (1) DK0839133T3 (de)
EA (1) EA000797B1 (de)
ES (1) ES2139373T3 (de)
FR (1) FR2736641B1 (de)
GR (1) GR3031409T3 (de)
IL (1) IL122812A (de)
MA (1) MA23929A1 (de)
MX (1) MX9800262A (de)
MY (1) MY114792A (de)
NO (1) NO309565B1 (de)
NZ (1) NZ313211A (de)
PE (1) PE11898A1 (de)
PL (1) PL324430A1 (de)
SK (1) SK282250B6 (de)
TN (1) TNSN96098A1 (de)
TW (1) TW438792B (de)
UY (1) UY24276A1 (de)
WO (1) WO1997003050A1 (de)
ZA (1) ZA965868B (de)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
FR2757855B1 (fr) * 1996-12-30 1999-01-29 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyl transferase, leur preparation et les compositions pharmaceutiques qui les contiennent
US6124465A (en) * 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
EP1042329A1 (de) * 1997-12-23 2000-10-11 Aventis Pharma S.A. Farnesyltransferase inhibitoren, verfahren zu ihrer herstellung, diese enthaltende pharmazeutische zubereitungen und ihre verwendung als arzneimittel
FR2772764B1 (fr) * 1997-12-23 2000-01-14 Rhone Poulenc Rorer Sa Nouveaux inhibiteurs de farnesyle transferase, leur preparation, les compositions pharmaceutiques qui les contiennent et leur utilisation pour la preparation de medicaments
FR2787327B1 (fr) * 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
FR2796641B1 (fr) 1999-07-22 2001-09-21 Aventis Pharma Sa Nouveau procede de preparation de composes benzoperhydroisoindole
US20020177575A1 (en) * 2001-05-04 2002-11-28 Ward Wakeland Identification of farnesyl-protein transferase as a target for systemic lupus erythematosus therapies
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
PE20070335A1 (es) 2005-08-30 2007-04-21 Novartis Ag Benzimidazoles sustituidos y metodos para su preparacion
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
KR101464385B1 (ko) 2006-04-19 2014-11-21 노파르티스 아게 ６-ｏ-치환된 벤즈옥사졸 및 벤조티아졸 화합물, 및 ｃｓｆ-１ｒ 신호전달의 억제 방법
AU2007300627B2 (en) 2006-09-22 2012-02-16 Merck Sharp & Dohme Corp. Method of treatment using fatty acid synthesis inhibitors
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
BRPI0806245B1 (pt) 2007-01-10 2022-01-25 Msd Italia S.R.L. Compostos de fórmula i e seus usos
CN101679266B (zh) 2007-03-01 2015-05-06 诺华股份有限公司 Pim激酶抑制剂及其应用方法
AU2008254425A1 (en) 2007-05-21 2008-11-27 Novartis Ag CSF-1R inhibitors, compositions, and methods of use
WO2009002495A1 (en) 2007-06-27 2008-12-31 Merck & Co., Inc. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
US7932036B1 (en) 2008-03-12 2011-04-26 Veridex, Llc Methods of determining acute myeloid leukemia response to treatment with farnesyltransferase
EP2413932A4 (de) 2009-04-01 2012-09-19 Merck Sharp & Dohme Hemmer der akt-aktivität
US8765747B2 (en) 2009-06-12 2014-07-01 Dana-Farber Cancer Institute, Inc. Fused 2-aminothiazole compounds
CA2777043C (en) 2009-10-14 2015-12-15 Schering Corporation Substituted piperidines that increase p53 activity and the uses thereof
EP2937345B1 (de) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Typ-ii-raf-kinase-hemmer
BR112012023021A2 (pt) 2010-03-16 2016-05-31 Dana Farber Cancer Inst Inc compostos de indazol e seus usos
EP2584903B1 (de) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Neue heterozyklische verbindungen als erk-hemmer
AU2011282614B2 (en) 2010-07-28 2015-11-26 Janssen Pharmaceutica Nv Methods of determining Acute Myeloid Leukemia response to treatment with farnesyltransferase inhibitors
CN103068980B (zh) 2010-08-02 2017-04-05 瑟纳治疗公司 使用短干扰核酸（siNA）的RNA干扰介导的联蛋白（钙粘蛋白关联蛋白质），β1（CTNNB1）基因表达的抑制
RU2745848C2 (ru) 2010-08-17 2021-04-01 Сирна Терапьютикс, Инк. ОПОСРЕДУЕМОЕ РНК-ИНТЕРФЕРЕНЦИЕЙ ИНГИБИРОВАНИЕ ЭКСПРЕССИИ ГЕНОВ ВИРУСА ГЕПАТИТА B (HBV) С ПРИМЕНЕНИЕМ МАЛОЙ ИНТЕРФЕРИРУЮЩЕЙ НУКЛЕИНОВОЙ КИСЛОТЫ (миНК)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
EP2613782B1 (de) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazolderivate als erk-hemmer
US9242981B2 (en) 2010-09-16 2016-01-26 Merck Sharp & Dohme Corp. Fused pyrazole derivatives as novel ERK inhibitors
WO2012058210A1 (en) 2010-10-29 2012-05-03 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA)
WO2012087772A1 (en) 2010-12-21 2012-06-28 Schering Corporation Indazole derivatives useful as erk inhibitors
WO2012143879A1 (en) 2011-04-21 2012-10-26 Piramal Healthcare Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
EP2770987B1 (de) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Neue verbindungen als erk-hemmer
JP6106685B2 (ja) 2011-11-17 2017-04-05 ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド Ｃ−ｊｕｎ−ｎ−末端キナーゼ（ｊｎｋ）の阻害剤
EP3919620A1 (de) 2012-05-02 2021-12-08 Sirna Therapeutics, Inc. Zusammensetzungen mit kurzer interferierender nukleinsäure (sina)
CA2882950A1 (en) 2012-09-28 2014-04-03 Merck Sharp & Dohme Corp. Novel compounds that are erk inhibitors
EP2909194A1 (de) 2012-10-18 2015-08-26 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 (cdk7)
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
SMT201700595T1 (it) 2012-11-28 2018-03-08 Merck Sharp & Dohme Composizioni e metodi per trattare il cancro
WO2014100065A1 (en) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Substituted imidazopyridines as hdm2 inhibitors
WO2014120748A1 (en) 2013-01-30 2014-08-07 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as hdm2 inhibitors
WO2015034925A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015058126A1 (en) 2013-10-18 2015-04-23 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of prolferative diseases
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
WO2015164614A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
US10870651B2 (en) 2014-12-23 2020-12-22 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
CN107427521B (zh) 2015-03-27 2021-08-03 达纳-法伯癌症研究所股份有限公司 细胞周期蛋白依赖性激酶的抑制剂
CA2986441A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
US10471055B2 (en) 2015-08-17 2019-11-12 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JOP20190055A1 (ar) 2016-09-26 2019-03-24 Merck Sharp & Dohme أجسام مضادة ضد cd27
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
HRP20210544T1 (hr) 2016-11-03 2021-08-20 Kura Oncology, Inc. Inhibitori farneziltransferaze za uporabu u liječenju raka
JP7160833B2 (ja) 2017-04-13 2022-10-25 サイロパ ビー．ブイ． 抗ｓｉｒｐアルファ抗体
EP3706742B1 (de) 2017-11-08 2023-03-15 Merck Sharp & Dohme LLC Prmt5-inhibitoren
WO2019094312A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2019113269A1 (en) 2017-12-08 2019-06-13 Kura Oncology, Inc. Methods of treating cancer patients with farnesyltransferase inhibitors
WO2019148412A1 (en) 2018-02-01 2019-08-08 Merck Sharp & Dohme Corp. Anti-pd-1/lag3 bispecific antibodies
EP3810132A4 (de) 2018-06-25 2022-06-22 Dana-Farber Cancer Institute, Inc. Kinaseinhibitoren der taire und ihre verwendungen
WO2020033282A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
CA3108388A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
WO2020033285A1 (en) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3833667B1 (de) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5-inhibitoren
CN113164477A (zh) 2018-12-14 2021-07-23 达纳-法伯癌症研究所股份有限公司 C-jun-n-末端激酶的吡唑并吡啶抑制剂及其用途
EP3902542A4 (de) 2018-12-28 2022-09-07 Dana-Farber Cancer Institute, Inc. Hemmer der cyclinabhängigen kinase 7 und verwendungen davon
US20220143006A1 (en) 2019-03-15 2022-05-12 Kura Oncology, Inc. Methods of treating cancer with farnesyltransferase inhibitors
ES3022307T3 (en) 2019-12-17 2025-05-28 Merck Sharp & Dohme Llc Prmt5 inhibitors
EP4076460B1 (de) 2019-12-17 2026-01-21 Merck Sharp & Dohme LLC 1,4-dihydro-2h-spiro[isoquinoline-3,4'-piperidin]-derivate als prmt5 inhibitoren zur behandlung von krebs
EP4303246A1 (de) 2022-07-04 2024-01-10 Covestro Deutschland AG Polyisocyanatgemisch
WO2024180169A1 (en) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Means and methods for diagnosing cancer and/or an acute inflammatory disease
DE212025000115U1 (de) 2024-07-30 2026-06-18 Sairopa B.V. Anti-SIRP Alpha-Antikörperformulierungen und ihre Verwendung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2492372A1 (fr) * 1980-10-21 1982-04-23 Cird Dihydroxy-1,8 anthrones-9 substituees en position 10 et leur utilisation en medecine humaine ou veterinaire et en cosmetique
KR100362338B1 (ko) * 1993-11-05 2003-04-08 워너-램버트 캄파니 단백질:파르네실트랜스퍼라아제의치환디-및트리펩티드억제제

Also Published As

Publication number Publication date
PE11898A1 (es) 1998-03-15
CO4700457A1 (es) 1998-12-29
NZ313211A (en) 1999-11-29
AR003143A1 (es) 1998-07-08
CZ291620B6 (cs) 2003-04-16
IL122812A0 (en) 1998-08-16
FR2736641B1 (fr) 1997-08-22
TW438792B (en) 2001-06-07
AU712194B2 (en) 1999-10-28
UY24276A1 (es) 2001-10-25
MA23929A1 (fr) 1997-04-01
MX9800262A (es) 1998-04-30
US5936097A (en) 1999-08-10
EP0839133B1 (de) 1999-10-06
TNSN96098A1 (fr) 2005-03-15
MY114792A (en) 2003-01-31
WO1997003050A1 (fr) 1997-01-30
FR2736641A1 (fr) 1997-01-17
SK2698A3 (en) 1998-07-08
CN1190389A (zh) 1998-08-12
DK0839133T3 (da) 2000-04-17
NO980094L (no) 1998-02-17
KR19990028856A (ko) 1999-04-15
CZ5498A3 (cs) 1998-04-15
PL324430A1 (en) 1998-05-25
SK282250B6 (sk) 2001-12-03
ES2139373T3 (es) 2000-02-01
CA2224414A1 (fr) 1997-01-30
GR3031409T3 (en) 2000-01-31
NO309565B1 (no) 2001-02-19
EA199800118A1 (ru) 1998-08-27
ZA965868B (en) 1997-01-29
EA000797B1 (ru) 2000-04-24
DE69604588T2 (de) 2000-05-18
CN1096448C (zh) 2002-12-18
IL122812A (en) 2001-04-30
DE69604588D1 (en) 1999-11-11
NO980094D0 (no) 1998-01-09
EP0839133A1 (de) 1998-05-06
JPH11511123A (ja) 1999-09-28
AU6522496A (en) 1997-02-10
BR9609440A (pt) 1999-06-29

Similar Documents

Publication Publication Date Title
GR3031409T3 (en) 4,9-ethano-benzo(f)isoindole derivatives as farnesyl transferase inhibitors
ATE215541T1 (de) (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
NO20024950D0 (no) 4-Merkaptopyrrolidinderivater som farnesyltransferaseinhibitorer
EP0833633A4 (de) Inhibitoren der farnesyl-protein-transferase
NO974457D0 (no) Inhibitorer for farnesylproteintransferase
EP0794789A4 (de) Prenyltransferase inhibitoren
DK1019395T3 (da) Farnesyltransferasehæmmende 2-quinolonderivater
FI951554A7 (fi) Imidatsolipitoisia farnesyyliproteiinitransferaasi-inhibiittoreita
EP0862435A4 (de) Inhibitoren der farnesyl-protein-transferase
EE9800262A (et) Farnesüül-proteiini transferaasi inhibiitorid
EE9800408A (et) Proteiinfarnesüültransferaasi inhibiitorid
EP0817629A4 (de) Farnesylprotein transferase inhibitoren
EP0668856A4 (de) Inhibitoren der farnesyl-proteintransferase.
ATE214367T1 (de) Farnesyl transferase inhibitoren
EP0817630A4 (de) Inhibitoren der farnesyl-protein transferase
ZA985211B (en) Benzo (5,6) cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
HK1030933A (en) Benzo(5,6)cycloheptapyridine compounds useful as farnesyl protein transferase inhibitors
EP0837857A4 (de) Inhibitoren der farnesyl-proteintransferase

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee